Balyasny Asset Management L.P.

Position in VRDN — Viridian Therapeutics, Inc.\DE

CIK 1218710 Chicago, IL

Position in VRDN

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$45,300,118

+$29,619,746 QoQ

Shares Held

2,315,957

+359.6% QoQ

Ownership

2.25%

of shares outstanding

% of Portfolio

0.10%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2021

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Balyasny Asset Management L.P. holds $2,162,785,356 across 177 Biotechnology names. VRDN ranks #11 (2.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	TERN	Terns Pharmaceuticals, Inc.	2,779,445	$146,532,340
2	ERAS	Erasca, Inc.	5,143,985	$83,229,677
3	TNGX	Tango Therapeutics, Inc.	3,826,659	$80,053,706
4	APLS	Apellis Pharmaceuticals, Inc.	1,917,501	$77,141,065
5	BMRN	Biomarin Pharmaceutical Inc	1,362,752	$76,981,860
6	CYTK	Cytokinetics Inc	992,545	$65,418,640
7	DAWN	Day One Biopharmaceuticals, Inc.	2,625,235	$56,285,038
8	FOLD	AMICUS THERAPEUTICS, INC.	3,827,513	$55,345,837

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$45,300,118	2,315,957	+359.6%	Shares	Sole	2026-05-15
2025-12-31	$15,680,372	503,868	+148.4%	Shares	Sole	2026-02-17
2025-09-30	$4,376,877	202,821	+55.2%	Shares	Sole	2025-11-14
2024-12-31	$2,505,921	130,721	-61.4%	Shares	Sole	2025-02-14
2024-09-30	$7,714,274	339,089	+722.8%	Shares	Sole	2024-11-14
2023-12-31	$897,640	41,214	+195.0%	Shares	Sole	2024-02-14
2023-09-30	$214,284	13,969	-95.4%	Shares	Sole	2023-11-14
2022-12-31	$8,895,963	304,552	+79.6%	Shares	Sole	2023-02-14
2022-09-30	$3,477,039	169,529	+939.9%	Shares	Other	2022-11-15
2022-03-31	$301,442	16,303	-86.4%	Shares	Sole	2022-05-16
2021-06-30	$2,185,252	119,478	-0.1%	Shares	Sole	2021-08-16
2021-03-31	$1,998,114	119,576	—	Shares	Sole	2021-05-17
No filing history on record for this holder in this stock.